NIMH Phytoestrogen, Depression Studies Begin Initial Enrollment
This article was originally published in The Tan Sheet
Executive Summary
Recruitment screening has begun for an NIH randomized, placebo-controlled clinical study on the effects of treatment with Novagen's Rimostil phytoestrogen supplement and raloxifene (Eli Lilly's Evista) on peri-menopausal depression
You may also be interested in...
Soy HRT Potential May Be As Complement Rather Than Substitute
Soy and purified soy isoflavones should be explored for complementary effects on hormone replacement therapy rather than for potential as an HRT replacement, according to speakers at a recent conference
Inconclusive St. John’s Wort Trial Prompts Queries On Study Design, Setting
The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association
Rimostil
Novogen expects nationwide distribution of isoflavone menopause supplement for "bone and heart health in women" to be completed within the next several months. The product currently is available in health food stores around San Francisco. One tablet contains 57 mg of Clovone, a proprietary blend of the isoflavones fomononetin, daidzein, biochanin A and genistein. Suggested retail price for a 28-day supply of Rimostil is $29.95. Novogen also markets Promensil for perimenopausal women and Trinovin for prostate health